Common Contracts
1 similar Study Agreement contracts
Amendment # 1 TO Clinical Study AGREEMENT DODATEK # 1 KE SMLOUVĚ O KLINICKÉM HODNOCENÍStudy Agreement • May 10th, 2021
This Amendment (the "Amendment") to the Clinical Study Agreement, dated 8 September 2020 (the “Agreement”), for the clinical study (the “Study”) sponsored by Oncopeptides AB (publ), having its registered place of business at Västra Trädgårdsgatan 15, S-11153 Stockholm, Sweden (the "Sponsor"), conducted in accordance with the protocol OP-108 “A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma” and any amendments thereto (the “Protocol”), is made by and between: Tento Dodatek (dále jen „Dodatek“) ke Smlouvě o klinickém hodnocení uzavřené dne 8 září 2020 (dále jen „Smlouva“) ke klinické studii (dále jen „Studie“) zadané společností Oncopeptides AB (publ), se sídlem Västra Trädgårdsgatan 15, S-11153 Stockholm, Švédsko (dále jen „Zadavatel”) a prováděné v souladu s protokolem OP-108 „Randomizovaná, kontrolovaná, otevřená studie fáze 3, hodnotící lék Melflu
